Traveler's Diarrhea Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

LAS VEGAS, March 27, 2019 /PRNewswire/ --

• Approximately 10 million people develop Traveler's Diarrhea every year across the United States.
• The US accounts for the 43.4% and 40.77% of the total Incident cases out of all the Traveler's Diarrhea cases in 7 major markets in 2017.
• The highest percentage of diagnosed Traveler's Diarrhea incident population in the Germany followed by Italy among the EU5 Countries in 2017.

DelveInsight launched Traveler's Diarrhea - Market Insights, Epidemiology and Market Forecast- 2028

1. Traveler's Diarrhea market report covers a descriptive overview and comprehensive insight of the Traveler's Diarrhea epidemiology and Traveler's Diarrhea market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Traveler's Diarrhea market report provides the insights on the current and emerging therapies.
3. The Traveler's Diarrhea market report provides global historical and forecasted market covering drug outreach in 7 MM.
4. The Traveler's Diarrhea market report provides an edge that will help in developing business strategies, by understanding trends shaping and driving the Traveler's Diarrhea market.

"Around 25%-50% of individuals is expected to experience diarrhea as a result of ingesting fecally contaminated water or food."

Traveler's Diarrhea total market size is calculated by including the market size for both emerging and current therapies. Expected launch of potential therapies may increase Traveler's Diarrhea market size in the coming years, assisted by an increase in diagnosed Traveler's Diarrhea incident population. Owing to the positive outcomes of the several drug candidates during the developmental stage by key players such as Scandinavian Biopharma, Procter and Gamble, etc. they have the potential to create a significant positive shift in the Traveler's Diarrhea Market Size. The United States accounts for the largest Traveler's Diarrhea market size, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Traveler's Diarrhea treatment therapies comprise of oral hydration and diet modification strategy followed by Anti-motility drugs or antidiarrheal drugs (also known as symptomatic therapy) and Antibiotics/Antimicrobials. The current Traveler's Diarrhea US market is dominated by the use of Antibiotics such as fluoroquinolones comprising ciprofloxacin, ofloxacin, norfloxacin and levofloxacin. Antibioticsforms the first line of treatment. Antibiotics, anti-motility drugs (for symptomatic relief) and Dukarol (Vaccine) are extensively being used as an off label therapy. The current market also holds a single approved therapy Xifaxan by Salix Pharmaceuticals. Xifaxan has shown to capture the market share post approval.

Traveler's Diarrhea current market will increase in the upcoming years with the emergence of several upcoming therapies with prophylactic action and few belonging to the same class of antibiotics and anti-diarrheal agents. The late stage product Bismuth Subsalicylate has emerged as a promising option to enter the Traveler's Diarrhea market in 2021.

Get a demo of the report: https://bit.ly/2JC8VaP

The key players in Traveler's Diarrhea market are:

1. Procter and Gamble
2. Scandinavian Biopharma
3. Cosmo Pharmaceuticals
4. Salix Pharmaceuticals

Drugs covered

1. Etvax
2. Bismuth Subsalicylate
3. Aemcolo/Relafalk
4. Xifaxan
   And many others

Table of contents

1 Traveler's Diarrhea Key Insights

2 Traveler's Diarrhea Market Overview at a Glance

3 Traveler's Diarrhea Disease Background and Overview

3.7 Traveler's Diarrhea Diagnosis

4 Traveler's Diarrhea Epidemiology and Patient Population

5 Traveler's Diarrhea Country Wise-Epidemiology

5.1 United States

5.2 EU5 Countries

5.3 Germany

5.4 France

5.5 Italy

5.6 Spain

5.7 United Kingdom

5.8 Japan

6 Traveler's Diarrhea Treatment

7 Traveler's Diarrhea Unmet Needs

8 Traveler's Diarrhea Marketed Drugs

8.1 Aemcolo/Relafalk: Cosmo Pharmaceuticals

8.2 Xifaxan: Salix Pharmaceuticals

9 Traveler's Diarrhea Emerging Drugs

9.1 Traveler's Diarrhea Key Cross Competition

9.2 Etvax: Scandinavian Biopharma

9.3 Bismuth Subsalicylate: Procter and Gamble

10 Traveler's Diarrhea 7 Major Market Analysis

11 Traveler's Diarrhea United States Market Outlook

12 Traveler's Diarrhea EU-5 Countries Market Outlook

12.1 Germany

12.2 France

12.3 Italy

12.4 Spain

12.5 United Kingdom

13 Traveler's Diarrhea Japan Market Outlook

14 Traveler's Diarrhea Market Drivers

15 Traveler's Diarrhea Market Barriers

16 Appendix

16.1 Report Methodology

17 DelveInsight Capabilities

18 Disclaimer

19 About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Related reports:

1. Traveler's Diarrhea - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2019- The report contains historical and forecasted global sales till 2021 for each marketed product and forecasted sales till 2021 for emerging Phase III products for Traveler's Diarrhea. It includes comprehensive coverage of the emerging therapies (Phase III) for Traveler's Diarrhea including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information.
2. Traveler's Diarrhea - Pipeline Insight, 2019 – The report provides an overview of therapeutic pipeline activity for Traveler's Diarrhea across the complete product development cycle including all clinical and non-clinical stages. It comprises of detailed profiles of Traveler's Diarrhea therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information.

Contact us:
Shruti Thakur
info@delveinsight.com
+91-9650213330